Axsome Therapeutics, Inc. (NASDAQ: AXSM) Insider Trading and Financial Overview

Axsome Therapeutics' CEO and a significant shareholder, Herriot Tabuteau, sold 31,261 shares, reducing his holdings significantly.Director Mark Saad also sold a large portion of his shares, decreasing his ownership by 78.98%.The company's stock has experienced significant volatility over the past year, with a market capitalization of approximately $8.60 billion and a challenging price-to-earnings (P/E) ratio of -38.26.Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company focused on develop ...